JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications

OBJECTIVES: To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. METHODS: Systematic searches of databases were performed, to December 2022, to identify phase II/III/I...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Mark D, Stovin, Christopher, Alveyn, Edward, Adeyemi, Olukemi, Chan, Chun Kit David, Patel, Vishit, Adas, Maryam A, Atzeni, Fabiola, Ng, Kenrick K H, Rutherford, Andrew I, Norton, Sam, Cope, Andrew P, Galloway, James B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359573/
https://www.ncbi.nlm.nih.gov/pubmed/37247942
http://dx.doi.org/10.1136/ard-2023-224049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359573/
https://www.ncbi.nlm.nih.gov/pubmed/37247942
http://dx.doi.org/10.1136/ard-2023-224049

Ejemplares similares